Last Week in Biomedicine | May 18–22 | Part 1 of 2: Retatrutide Obesity, Sac-TMT Cancer Win

This week the biggest story in clinical trial results came out of an obesity trial: Eli Lilly's retatrutide — a once-weekly shot that activates three different appetite-and-metabolism hormones (GIP, GLP-1, and glucagon) at the same time — helped adults with obesity lose an average of roughly 30% of their body weight at 80 weeks. That level of weight loss was previously only seen with bariatric surgery. We also unpack a TROP-2 antibody-drug conjugate from Merck and Kelun-Biotech thatscored back-to-back Phase 3 wins in two tough cancers, plus a novel approach to gout and a new mechanism for stubborn high blood pressure.
In Part 1 we cover:1. Eli Lilly — Retatrutide for Obesity (Phase 3)2. Merck — Sacituzumab Tirumotecan (sac-TMT) for Advanced or Recurrent Endometrial Cancer (Phase 3)3. Kelun-Biotech — Sacituzumab Tirumotecan (sac-TMT) for First-Line Advanced Triple-Negative Breast Cancer (Phase 3)
4. Sobi — Pozdeutinurad for Gout (Phase 3)5. Mineralys Therapeutics — Lorundrostat for Uncontrolled and Resistant Hypertension, Including Patients With Chronic Kidney Disease (Phase 3)
The retatrutide readout matters because obesity affects more than a billion people globally, and an injectable medicine reaching surgery-level weight loss could change how doctors and patients think about treatment — moving it from a'maybe later' option to a frontline tool. The same week's sac-TMT cancer wins point to a new class of 'guided-missile' chemotherapy that homes in on the TROP-2 protein found on many tumors, and the gout and hypertension readoutsboth crack open therapy classes that have been stuck for decades.
Part 2 drops Thursday. Subscribe at TrialBreaks.com#biomedicine #clinicaltrials #science #obesity #GLP1 #oncology #breastcancer #endometrialcancer #ADC #cardiology #hypertension #gout #immunotherapy #drugdiscovery

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(17)

Last Week in Biomedicine | Jun 29–Jul 3 | Part 2 of 2: Baby Pompe Disease Trial, DLBCL Combo Win

Part 2 covers three more standout stories from the same week: a Phase 3 trial that gives babies with a devastating enzyme disease a fighting chance, a first-of-its-kind cell therapy approved to make b...

9 Heinä 36min

Last Week in Biomedicine | Jun 29–Jul 3 | Part 1 of 2: CRISPR for Toddlers, KRAS Lung Cancer Win

CRISPR gene editing crossed a major line this week: the FDA now allows Casgevy — the first CRISPR therapy of any kind — for children as young as 2 with sickle cell disease, meaning we can potentially ...

7 Heinä 43min

Last Week in Biomedicine | June 22–26 | Part 2 of 2: Thyroid Eye Disease, ADHD + Anxiety, Skyrizi Kids

Part 2 covers a new drug for the bulging-eye autoimmune disease, the first Phase 3 ADHD trial designed for patients who also have anxiety, and a major pediatric expansion for a top-selling psoriasis b...

2 Heinä 41min

Last Week in Biomedicine | June 22–26 | Part 1 of 2: LSD Depression Phase 3, Trodelvy TNBC Approval

This week, an LSD-based therapy hit its main goal in a Phase 3 depression trial — and two huge breast cancer approvals landed at the FDA on the same week. In Part 1 we cover:1. Definium Therapeutics —...

30 Kesä 36min

Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug

Part 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work forboth forms of hyper...

25 Kesä 25min

Last Week in Biomedicine | June 14–20 | Part 1 of 2: CRISPR HAE Cure, Narcolepsy Orexin Breakthrough

This week opened with one of the most significant gene-editing milestones in clinical medicine: a single CRISPR infusion cut hereditary angioedema attacks by 87 percent in a Phase 3 trial, published t...

23 Kesä 34min

Last Week in Biomedicine | June 6–13 | Part 2 of 2: CagriSema Diabetes, Sickle Cell Plenary

Part 2 of our June 6–13 wrap-up: Novo Nordisk's CagriSema beats semaglutide alone in three Phase 3 diabetes trials, Takeda's zasocitinib pill outperforms Sotyktu head-to-head in psoriasis, and Agios's...

18 Kesä 21min

Last Week in Biomedicine | June 6–13 | Part 1 of 2: Retatrutide Weight Loss, Weekly HIV Pill

A blockbuster week in biomedicine — Eli Lilly's retatrutide produced weight loss approaching bariatric surgery in Phase 3, and Gilead and Merck's once-weekly oral HIV pill cleared two Phase 3 trials. ...

16 Kesä 20min